Physician profile
Kourosh Rezania
NPI 1376694356
$176,673.21
in general payments reported to CMS, 2019-2025
19 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $22K · 2021: $21K · 2022: $20K · 2023: $20K · 2024: $12K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $9,911 · Travel and Lodging: $5,666 · Food and Beverage: $2,591 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,183.76 |
| Consulting Fee | $9,910.50 |
| Travel and Lodging | $5,665.57 |
| Food and Beverage | $2,591.06 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $44,514.13 | 2020-2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $36,015.80 | 2021-2025 | Hyqvia |
| Akcea Therapeutics, INC. | $34,710.38 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $28,671.30 | 2020-2023 | Amvuttra |
| Alexion Pharmaceuticals, INC. | $14,832.91 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $4,938.08 | 2019 | |
| Tanabe Pharma America, INC. | $4,478.84 | 2019 | |
| Janssen Biotech, INC. | $2,820.00 | 2025 | |
| Argenx US, INC. | $2,315.98 | 2022 | |
| Grifols Shared Services North America, INC. | $1,819.25 | 2025 | Gamunex-C |
| Ucb Sa | $1,124.89 | 2019 | |
| Genzyme Corporation | $149.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $113.48 | 2024 | |
| Ucb, INC. | $106.99 | 2023 | |
| Abbvie INC. | $26.21 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $18.06 | 2024 | Wainua |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kourosh Rezania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.